My top idea for conservative, income-oriented investors in the coming year is a closed-end fund that invests in public and privately-held companies doing work in the life sciences arena, writes Nate Pile of Nate's Notes.
The life sciences industry includes stocks in biotechnology, pharmaceuticals, diagnostics, managed healthcare and medical equipment, and healthcare information technology and services.
This recommended fund��ambrecht & Quist Life Sciences Fund (HQL)��as also our top pick last year, and the fund rose 44% in 2013.
In addition to rising in value, the fund has a dividend policy of paying out 2% of its net asset value of each quarter.
By choosing to take this payout in the form of a dividend reinvestment, rather than cash, investors have done very well for themselves as they've watched, both the size of their holdings, and the share price itself, increase as the years have rolled by.
To be sure, you will always be able to get more bang for your buck by owning individual biotech stocks.
Hot Bank Companies To Buy Right Now: Durata Therapeutics Inc (DRTX)
Durata Therapeutics, Inc., incorporated on November 4, 2009, is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company enroll and dose patients in two global Phase III clinical trials with its product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections (abSSSI). Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing. In addition to abSSSI, the Company focuses on the development of dalbavancin for additional indications, including osteomyelitis, diabetic foot infection and pneumonia.
As of December 31, 2011, Dalbavancin had already completed three Phase III clinical trials, in which more than 1,000 patients in total received dalbavancin. Dalbavancin achieved its primary efficacy endpoint of non-inferiority in each of these three completed Phase III clinical trials when compared to linezolid, cefazolin or vancomycin, three of the standard-of-care agents for uncomplicated skin and skin structure infections (uSSSI), and complicated skin and skin structure infections (cSSSI). Its two ongoing Phase III clinical trials are designed to compare dalbavancin to vancomycin, with an option to switch to oral linezolid, under the new FDA draft guidance.
The Company competes with Pfizer, Cubist Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., Sanofi-Aventis Ltd., The Medicines Company, Trius Therapeutics, Inc., Cempra, Inc., Rib-X Pharmaceuticals, Inc., Paratek Pharmaceuticals, Inc., Nabriva Therapeutics AG, Tetraphase Pharmaceuticals, Inc. and Furiex Pharmaceuticals, Inc.
Advisors' Opinion:- [By Lisa Levin]
Durata Therapeutics (NASDAQ: DRTX) shares climbed 5.30% to $14.18. The volume of Durata Therapeutics shares traded was 861% higher than normal. The FDA Advisory Committee unanimously recommended the approval of Durata's Dalvance.
- [By Bob's Stocks]
Durata Therapeutics (DRTX) is developing Dalbavancin, a once a week, intravenous antibiotic product candidate, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. The company is expected to file a NDA (New Drug Application) at any moment and MAA (Marketing Authorization Application) at the end of 2013.
Top 5 Life Sciences Stocks To Invest In 2014: United States Cellular Corporation(USM)
United States Cellular Corporation operates as a wireless telecommunications service provider in the United States. The company offers wireless voice and data services to retail consumer and business customers. It provides wireless services in postpaid service plans with voice, messaging, and data services; and prepaid service plans with minutes, messaging, and data services for a monthly fee. The company also offers various additional features, including caller ID blocking, call forwarding, voicemail, call waiting, and three-way calling; and data usage features consisting of Web browsing, email services, instant messaging, text messaging, and picture and video messaging. As of December 31, 2010, it provided wireless voice and data services to 6.1 million customers in 26 states. In addition, the company operates retail stores that sell a range of wireless devices, including handsets, modems, and tablets, as well as accessories, such as carrying cases, hands-free devices, b atteries, battery chargers, memory cards, and other items to consumers and small businesses. Further, it sells wireless devices to agents and other third-party distributors for resale; operates service facilities that provide servicing and repair for wireless devices; and enables customers to activate service and purchase wireless devices online. The company?s business customers include small-to-mid-size businesses in various industries, including construction, retail, professional services, and real estate. It offers its products and services through retail sales and service centers, direct sales, and independent agents. The company was founded in 1983 and is based in Chicago, Illinois. United States Cellular Corporation is a subsidiary of Telephone and Data Systems, Inc.
Advisors' Opinion:- [By Tim Beyers]
Low price-to-book stocks suffer from a similar problem. Who cares if the stock sells for a discount to its assets if the company can't earn a good return on said assets? United States Cellular (NYSE: USM ) has seen its returns on assets and equity decline steadily since 2011. Thus, despite a history of trading near or below book value, the stock is down 22% since the beginning of last year.
Investment strategies are just that: strategies. Recognize that every company is different. Analyze the underlying strengths and weaknesses before you buy. Because the more you understand about what drives a business to grow, the more likely it is you'll pay a fair price to own a piece of it, Tim says.
Do you agree? Please watch the video to get Tim's full take, and then leave a comment to let us know which investment strategies have worked best for you.
Top 5 Life Sciences Stocks To Invest In 2014: Wells Fargo Advantage Income Opportunities Fund (EAD)
Evergreen Income Advantage Fund (the Fund) is a diversified closed-end management investment company. The primary investment objective of the Fund is to seek a high level of current income.
During the fiscal year ended April 30, 2005, the Fund's investment portfolio included Marquee Holdings, Inc., Mediacom LLC, American Achievement Corp., CSK Auto, Inc., Oxford Industries, Inc., B&G Foods Holdings Corp. and Chiquita Brands International, Inc.
Advisors' Opinion:- [By Namitha Jagadeesh]
European Aeronautic, Defence & Space Co. (EAD) rose 1.8 percent to 47.28 euros, the highest price since it sold shares to the public in 2000. Deutsche Lufthansa AG split an order for 59 wide-body aircraft valued at $19 billion between EADS unit Airbus SAS and Boeing Co.
- [By Jim Jubak]
Precision Castparts' impressive growth in the June quarter was largely a result of acquisitions. Organic sales growth year over year came to just 2%. Most of the time I don't like growth stocks that are fueled by acquisition since these deals can hide the true (frequently negative) trend in core sales and earnings growth. But in the case of Precision Castparts, an acquisition strategy makes sense to me, because it is a reflection of what's going on in the aerospace sector. Companies like Boeing (BA) and Airbus (EAD) are looking to simplify their supply chain and to deal with fewer suppliers. Rolling up part of the supply chain under one roof, which is what Precision Castparts is doing right now, is a way to gain a bigger share of the business of these big end customers.
Top 5 Life Sciences Stocks To Invest In 2014: Model N Inc (MODN)
Model N, Inc., incorporated on December 14, 1999, is a provider of revenue management solutions for the life science and technology industries. The Company�� solutions enable its customers to maximize revenues and reduce revenue compliance risk by transforming their revenue lifecycle from a series of tactical, disjointed operations into a strategic end-to-end process. The Company�� customers use its application suites to manage mission-critical functions, such as pricing, contracting, incentives and rebates. Its solutions include two complementary suites of software applications, Revenue Management Enterprise and Revenue Management Intelligence. On January 18, 2012, the Company acquired certain assets of LeapFrogRx, Inc. (LeapFrogRx), a privately held cloud-based analytics solution provider for the pharmaceutical industry.
The Company provides solutions that span the organizational and operational boundaries of functions such as sales, marketing and finance, and serve as a system of record for key revenue management processes including pricing, contracts, rebates and regulatory compliance. Its application suites are purpose-built for the life science and technology industries and are designed to work with enterprise resource planning (ERP) and customer relationship management (CRM) applications that do not typically provide revenue management capabilities by enabling real-time pricing, managing contracts and automating channel incentives management, including rebates.
Revenue Management Enterprise suite
A broad set of transactional applications that serve as a system of record for, and automate the execution of revenue management processes such as incentive and rebate management, pricing and contracting. This suite includes its Price Management, Deal Management, Contract Management, Incentive and Rebate Management and Regulatory Compliance Management applications, which can be purchased together as a suite or as separate stand-alone applications.
Revenue Management Intelligence suiteA broad set of intelligence applications that provide the analytical insights to define and optimize revenue management strategies. This suite includes its Price Strategy, Brand Strategy, Channel Strategy, Managed Markets Strategy and International Reference Pricing applications, which can be purchased together as a suite or as separate stand-alone applications.
Advisors' Opinion:- [By Lee Jackson]
Model N Inc. (NYSE: MODN) develops applications, such as managed care and government pricing, for life science companies and channel incentives based on design wins for technology companies. The company’s customers use its application suites to manage mission-critical functions, such as pricing, contracting, incentives and rebates. The company had a recent initial public offering (IPO) that traded as high as $24.80 before badly missing earnings and being taken to the woodshed. Deutsche Bank still rates it as a stock to buy and has a $12 price target. The consensus target is at $15. The stock closed Friday at $9.88.
- [By Rick Munarriz]
I went out on a limb last week, and now it's time to see how that decision played out.
I predicted that Model N (NYSE: MODN ) would post a smaller loss than analysts were expecting. The provider of revenue management solutions has been a dud since going public nearly a year ago, but one thing it has consistently done is post a smaller deficit than what the pros are forecasting. Wall Street was settling for a loss of $0.12 a share, and Model N sported only $0.03 a share in red ink. The stock soared 19% on Tuesday after the better-than-expected report. I was right. After more than a year of predicting that the tech-heavy Nasdaq would outperform the Dow Jones Industrial Average � (DJINDICES: ^DJI ) , I mixed things up two weeks ago. I simply predicted that the Dow would bounce back after plunging 3.5% and 1.1% over the prior two weeks. I repeated the call this time around, and the Dow responded with a hearty 2.3% gain. I was right.� My final call was for LeapFrog (NYSE: LF ) to beat Wall Street's income estimates in its latest quarter. The maker of electronic learning toys has been routinely beating Wall Street projections over the past year. I was banking on a repeat performance, but it wasn't to be. LeapFrog merely broke even on a sharper drop in revenue than expected. Analysts had been braced for a profit of $0.14 a share. I was wrong.Two out of three? I can do better than that. Let me once again whip out my trusty, dusty, and occasionally accurate crystal ball to make three calls that may play out over the next few trading days.
No comments:
Post a Comment